UMIN-CTR Clinical Trial

Recruitment status Terminated
Unique ID issued by UMIN UMIN000015290
Receipt No. R000017787
Scientific Title Evaluation of osteoporosis treatments in patients undergoing TKA.
Date of disclosure of the study information 2014/09/30
Last modified on 2022/08/02 (Ver. 5)

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information
Public title Evaluation of osteoporosis treatments in patients undergoing TKA.
Acronym The influence of the drug for the treatment of osteoporosis on the proximal tibia
Scientific Title Evaluation of osteoporosis treatments in patients undergoing TKA.
Scientific Title:Acronym The influence of the drug for the treatment of osteoporosis on the proximal tibia
Region
Japan

Condition
Condition Osteoarthritis of the knee
Osteoporosis
Classification by specialty
Orthopedics
Classification by malignancy Others
Genomic information NO

Objectives
Narrative objectives1 Investigating the influence of the drug for the osteoporosis on the tibial lateral plateau
Basic objectives2 Efficacy
Basic objectives -Others
Trial characteristics_1
Trial characteristics_2
Developmental phase

Assessment
Primary outcomes Bone density at lumbar spine, bone metabolism markers (PINP, ucOC, TRACP-5b), KL score, KSS, CT on knee, and density and structure of excised samples.
Key secondary outcomes

Base
Study type Interventional

Study design
Basic design Parallel
Randomization Non-randomized
Randomization unit
Blinding Open -no one is blinded
Control Active
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment

Intervention
No. of arms 2
Purpose of intervention Treatment
Type of intervention
Medicine
Interventions/Control_1 Resedronate 17.5mg/week
Interventions/Control_2 Teriparatide 56.5ug/week
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10

Eligibility
Age-lower limit

Not applicable
Age-upper limit

Not applicable
Gender Male and Female
Key inclusion criteria Osteoporosis patients with high risk of bone fracture who is scheduled to have either BP or Teriparatide treatment* prior to TKA.

* BP (Resedronate 17.5/week) or Teriparatide 56.5ug/week is administered 3 months prior to TKA.
Key exclusion criteria none
Target sample size 20

Research contact person
Name of lead principal investigator
1st name Kenichiro
Middle name
Last name Takashiba
Organization Medical Co. LTA Fukuoka Mirai hospital
Division name Bone and joint center
Zip code 8130017
Address 3-5-1 Kashiiteriha Higashi-ku Fukuoka city
TEL 0926623535
Email k-takashiba@fukuoka-mirai.jp

Public contact
Name of contact person
1st name Kenichiro
Middle name
Last name Takashiba
Organization Medical Co. LTA Fukuoka Mirai hospital
Division name Bone and joint center
Zip code 8130017
Address 3-5-1 Kashiiteriha Higashi-ku Fukuoka city
TEL 0926623535
Homepage URL
Email k-takashiba@fukuoka-mirai.jp

Sponsor
Institute Medical Co. LTA Fukuoka Mirai hospital
Institute
Department

Funding Source
Organization Health Outcome Research Institute
Organization
Division
Category of Funding Organization Non profit foundation
Nationality of Funding Organization

Other related organizations
Co-sponsor
Name of secondary funder(s)

IRB Contact (For public release)
Organization Hakata Clinic IRB
Address 6-18 Tenyamachi, Hakata-ku, Fukuoka
Tel 0922387701
Email miyako-koga@lta-med.com

Secondary IDs
Secondary IDs NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW

Institutions
Institutions

Other administrative information
Date of disclosure of the study information
2014 Year 09 Month 30 Day

Related information
URL releasing protocol
Publication of results Unpublished

Result
URL related to results and publications
Number of participants that the trial has enrolled
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description

Progress
Recruitment status Terminated
Date of protocol fixation
2014 Year 07 Month 15 Day
Date of IRB
2014 Year 07 Month 18 Day
Anticipated trial start date
2014 Year 10 Month 01 Day
Last follow-up date
2022 Year 08 Month 01 Day
Date of closure to data entry
Date trial data considered complete
Date analysis concluded

Other
Other related information

Management information
Registered date
2014 Year 09 Month 30 Day
Last modified on
2022 Year 08 Month 02 Day


Link to view the page
URL(English) https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000017787